Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.63 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.63 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11460456 | 0.93 | IGF1R (0.70) | IGF1RGAAMAPTALDH1A1MAPK1 | |
| SCHEMBL13875132 | 0.90 | IGF1R (0.65) | IGF1RGAAMAPTALDH1A1MAPK1 | |
| SCHEMBL11453795 | 0.85 | IGF1R (0.67) | IGF1RGAAMAPTALDH1A1MAPK1 | |
| SCHEMBL14355261 | 0.85 | CACNA1G (0.67) | IGF1RGAAMAPTALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL8576435 | 0.84 | IGF1R (0.65) | IGF1RGAAMAPTALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL11723131 | 0.82 | IGF1R (0.57) | IGF1RGAAMAPTALDH1A1MAPK1 | |
| SCHEMBL4754252 | 0.82 | GAA (0.68) | IGF1RGAAMAPTALDH1A1MAPK1 | |
| SCHEMBL8272363 | 0.82 | IGF1R (0.57) | IGF1RGAAMAPTALDH1A1MAPK1 | |
| SCHEMBL8373462 | 0.81 | SIGMAR1 (0.69) | IGF1RMAPTALDH1A1MAPK1LMNA | |
| SCHEMBL2017995 | 0.81 | MAPT (0.74) | IGF1RGAAMAPTALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059948-A1 | QUINOLINE, NAPHTHALENE AND CONFORMATIONALLY CONSTRAINED QUINOLINE OR NAPHTHALENE DERIVATIVES AS ANTI-MYCOBACTERIAL AGENTS | THE INSTITUTE OF MOLECULAR MEDICINE (IN) | 2011-03-10 | — | — | US | disclosed |
| US-20110059948-A1 | QUINOLINE, NAPHTHALENE AND CONFORMATIONALLY CONSTRAINED QUINOLINE OR NAPHTHALENE DERIVATIVES AS ANTI-MYCOBACTERIAL AGENTS | THE INSTITUTE OF MOLECULAR MEDICINE (IN) | 2011-03-10 | — | — | US | disclosed |
| WO-2009091324-A1 | QUINOLINE, NAPHTHALENE AND CONFORMATIONALLY CONSTRAINED QUINOLINE OR NAPHTHALENE DERIVATES AS ANTI-MYCOBACTERIAL AGENTS | CHATTOPADHYAYA JYOTI (SE) | 2009-07-23 | — | — | WO | disclosed |
| US-4203986-A | TRANQUILIZERS, SEDATIVES, ANTITUSSIVE AGNETS | METABIO-JOULLIE (FR) | 1980-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059948-A1 | QUINOLINE, NAPHTHALENE AND CONFORMATIONALLY CONSTRAINED QUINOLINE OR NAPHTHALENE DERIVATIVES AS ANTI-MYCOBACTERIAL AGENTS | NQO1, NQO2, NDUFV1 | IGF1R 4812/4885ADRA2A 1570/4885ADRA2B 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.